NTRA Stock Falls -19% In 10-day Spree On Insider Selling And ‘Sell’ Rating
Natera (NTRA) – a provider of non-invasive prenatal and miscarriage molecular tests – hit a 10-day losing streak, with cumulative losses over this period amounting to -19%. The company’s market cap has crashed by about $6.3 Bil over the last 10 days and currently stands at $27 Bil.
The stock has YTD (year-to-date) return of 14.0% compared to -0.7% for S&P 500. This calls for a re-evaluation of the stock’s valuation to find out whether this is an opportunity or a trap.
What Triggered The Slide?
[1] Sustained Insider Selling by Key Executives
- Palantir At 80x Earnings: What Revenue Growth Rate Justifies The Valuation?
- Should You Pay Attention To Chevron Stock’s Momentum?
- What Is Happening With Caterpillar Stock?
- What Can Trigger Microsoft Stock’s Slide?
- Is Microsoft Stock A Trap Or A Missed Opportunity?
- Earn 9.6% Today or Buy BSX 30% Cheaper – It’s a Win-Win
- Multiple insiders sold shares, including the CEO, CFO, and President
- Approximately 350,703 shares worth ~$82.2M sold by insiders in the last 90 days
- Impact: Increased investor fear, Heightened selling pressure
[2] Weiss Ratings ‘Sell’ Reiteration
- Weiss Ratings reissued a ‘sell (d-)’ rating on the stock
- Technical sell signals from short and long-term moving averages confirmed a downtrend
- Impact: Negative sentiment shift, Contrarian viewpoint to bullish consensus
Opportunity or Trap?
Below is our take on valuation.
There are only a couple of things to fear in NTRA stock given its overall Strong operating performance and financial condition. But given its Very High valuation, the stock appears Relatively Expensive (For details, see Buy or Sell NTRA).
But here is the real interesting point.
You are reading about this -19% move after it happened. The market has already priced in the news. To avoid the next loser before the headlines, you need predictive signals, not notifications. Our High Quality Portfolio has a risk model designed to reduce exposure to losers.
Returns vs S&P 500
The following table summarizes the return for NTRA stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | NTRA | S&P 500 |
|---|---|---|
| 1D | -4.1% | -1.2% |
| 10D (Current Streak) | -18.9% | -1.7% |
| 1M (21D) | -20.8% | -2.1% |
| 3M (63D) | 0.3% | 0.4% |
| YTD 2026 | -14.0% | -0.7% |
| 2025 | 44.7% | 16.4% |
| 2024 | 152.7% | 23.3% |
| 2023 | 55.9% | 24.2% |
Take a look at what history tells you about whether past dips like this have been buying opportunities or traps: NTRA Dip Buyer Analysis.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 85 S&P constituents with 3 days or more of consecutive gains and 50 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 36 | 25 |
| 4D | 16 | 7 |
| 5D | 8 | 4 |
| 6D | 13 | 3 |
| 7D or more | 12 | 11 |
| Total >=3 D | 85 | 50 |
Key Financials for Natera (NTRA)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $1.1 Bil | $1.7 Bil |
| Operating Income | $-446.2 Mil | $-222.3 Mil |
| Net Income | $-434.8 Mil | $-190.4 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ2 | 2025 FQ3 |
|---|---|---|
| Revenues | $546.6 Mil | $592.2 Mil |
| Operating Income | $-110.4 Mil | $-97.6 Mil |
| Net Income | $-100.9 Mil | $-87.5 Mil |
The losing streak NTRA stock is currently on doesn’t inspire much confidence among investors. In contrast, Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.